Therapeutic use of compounds

Abstract

A compound having the formula (I) R1-COOH. R1 is an alkyl or alkenyl group having a C7-11 backbone, optionally branched with a C1-6 alkyl group at any C position in the backbone, or a pharmaceutically acceptable salt, amide or ester thereof. The backbone of the alkyl or alkenyl group, and/or the branched alkyl groups, are optionally interrupted by one or more heteroatoms, provided that when R1 is an alkyl group having a C7 backbone, the branching does not consist only of a hexyl group at the a carbon of R1, or only of a methyl group at the γ carbon of R1, or of only single methyl groups at both the β and ω-1 carbons of R1, and provided that when R1 is an alkyl group having a C8 or C11 backbone, the branching does not consist only of a propyl group at the a carbon of R1.

The invention is claimed as follows: 
     
       1. A method for treating a seizure-related disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of 4-ethyloctanoic acid, wherein the therapeutically effective amount of the 4-ethyloctanoic acid is 1 to 20,000 μg/kg per dose. 
     
     
       2. The method according to  claim 1 , wherein the seizure-related disorder is epilepsy. 
     
     
       3. The method according to  claim 1 , wherein the therapeutically effective amount of the 4-ethyloctanoic acid is administered to the subject with one or more of a pharmaceutically acceptable carrier, a pharmaceutically acceptable adjuvant or a pharmaceutically acceptable vehicle. 
     
     
       4. The method according to  claim 1 , wherein the therapeutically effective amount of the 4-ethyloctanoic acid is administered to the subject orally. 
     
     
       5. The method according to  claim 1 , wherein the therapeutically effective amount of the 4-ethyloctanoic acid is administered in an orally acceptable dosage form selected from the group consisting of capsules, tablets, powders, granules, aqueous suspensions and solutions.